{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:51:12Z","timestamp":1769637072790,"version":"3.49.0"},"reference-count":24,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE:<\/jats:title><jats:p>To compare the efficacy of a porcine surfactant (poractant alfa) versus bovine surfactants (beractant and calfactant) with respect to clinical outcomes among preterm infants with respiratory distress syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>A search of major electronic databases, including Medline (1980\u20132010) and the Cochrane Central Register of Controlled Trials, for randomized controlled trials that compared poractant alfa versus beractant and\/or calfactant among preterm infants with respiratory distress syndrome who required intubation and surfactant treatment was performed. The primary outcome was oxygen requirement at a postmenstrual age of 36 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Five randomized controlled trials involving 529 infants compared poractant alfa versus beractant for rescue treatment. No trials studied surfactant prophylaxis, and none compared poractant alfa versus calfactant. The incidences of oxygen dependence at a postmenstrual age of 36 weeks were similar for poractant alfa and beractant. Infants treated with poractant alfa at 100 mg\/kg (low dose) or 200 mg\/kg (high dose) exhibited statistically significant reductions in deaths (relative risk: 0.51 [95% confidence interval: 0.30\u20130.89]), the need for redosing (relative risk: 0.71 [95% confidence interval: 0.57\u20130.88]), oxygen requirements, duration of oxygen treatment, and duration of mechanical ventilation. The test of heterogeneity yielded positive results for the latter 2 outcomes. The difference remained statistically significant for deaths and the need for redosing with high-dose poractant alfa but not for low dose poractant alfa.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>There were significant reductions in deaths and the need for redosing with high-dose poractant alfa but not low-dose poractant alfa, compared with beractant.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.2011-1395","type":"journal-article","created":{"date-parts":[[2011,11,29]],"date-time":"2011-11-29T05:19:04Z","timestamp":1322543944000},"page":"e1588-e1595","source":"Crossref","is-referenced-by-count":52,"title":["Efficacy of Porcine Versus Bovine Surfactants for Preterm Newborns With Respiratory Distress Syndrome: Systematic Review and Meta-analysis"],"prefix":"10.1542","volume":"128","author":[{"given":"Neetu","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy L.","family":"Hawley","sequence":"additional","affiliation":[{"name":"School of Medicine and Health Sciences, George Washington University, Washington, DC; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Board of Health Sciences Policy, Institute of Medicine, National Academy of Sciences, Derwood, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2011,12,1]]},"reference":[{"issue":"2","key":"2021120900404776300_B1","first-page":"CD001079","article-title":"Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants","author":"Soll","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2021120900404776300_B2","first-page":"CD000144","article-title":"Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome","author":"Soll","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2021120900404776300_B3","first-page":"CD001149","article-title":"Synthetic surfactant for respiratory distress syndrome in preterm infants","author":"Soll","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2021120900404776300_B4","first-page":"CD000141","article-title":"Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome","author":"Soll","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2021120900404776300_B5","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1038\/jp.2009.31","article-title":"Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials","volume":"29","author":"Ramanathan","year":"2009","journal-title":"J Perinatol"},{"issue":"2","key":"2021120900404776300_B6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1542\/peds.2007-3283","article-title":"Surfactant-replacement therapy for respiratory distress in the preterm and term neonate","volume":"121","author":"Engle","year":"2008","journal-title":"Pediatrics"},{"key":"2021120900404776300_B7","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions 4.2.6","author":"Higgins","year":"2006"},{"issue":"1","key":"2021120900404776300_B8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1542\/peds.74.1.127","article-title":"An international classification of retinopathy of prematurity","volume":"74","author":"International Committee for Classification of Retinopathy of Prematurity","year":"1984","journal-title":"Pediatrics"},{"issue":"4","key":"2021120900404776300_B9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0022-3476(78)80282-0","article-title":"Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm","volume":"92","author":"Papile","year":"1978","journal-title":"J Pediatr"},{"issue":"2","key":"2021120900404776300_B10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00431-003-1367-8","article-title":"Comparison of treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome","volume":"163","author":"Baroutis","year":"2004","journal-title":"Eur J Pediatr"},{"issue":"10","key":"2021120900404776300_B11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/jp.2010.20","article-title":"Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome","volume":"30","author":"Fujii","year":"2010","journal-title":"J Perinatol"},{"issue":"10","key":"2021120900404776300_B12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/jp.2010.21","article-title":"Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome","volume":"30","author":"Fujii","year":"2010","journal-title":"J Perinatol"},{"issue":"7","key":"2021120900404776300_B13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s12098-010-0097-y","article-title":"Complications among premature neonates treated with beractant and poractant alfa","volume":"77","author":"Gharehbaghi","year":"2010","journal-title":"Indian J Pediatr"},{"issue":"6","key":"2021120900404776300_B14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1651-2227.2005.tb01984.x","article-title":"A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome","volume":"94","author":"Malloy","year":"2005","journal-title":"Acta Paediatr"},{"issue":"3","key":"2021120900404776300_B15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-2004-823779","article-title":"A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants","volume":"21","author":"Ramanathan","year":"2004","journal-title":"Am J Perinatol"},{"issue":"1","key":"2021120900404776300_B16","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1136\/fn.72.1.F8","article-title":"Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome","volume":"72","author":"Speer","year":"1995","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"1","key":"2021120900404776300_B17","first-page":"8","article-title":"The choice of surfactant for treatment of respiratory distress syndrome in preterm infants: a review of the evidence","volume":"1","author":"Fox","year":"2005","journal-title":"Infant"},{"issue":"4","key":"2021120900404776300_B18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000092869","article-title":"Recent clinical trials of surfactant treatment for neonates","volume":"89","author":"Halliday","year":"2006","journal-title":"Biol Neonate"},{"issue":"1","key":"2021120900404776300_B19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clp.2006.12.005","article-title":"Animal-derived surfactants versus past and current synthetic surfactants: current status","volume":"34","author":"Moya","year":"2007","journal-title":"Clin Perinatol"},{"issue":"1","key":"2021120900404776300_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000151749","article-title":"Choosing a right surfactant for respiratory distress syndrome treatment","volume":"95","author":"Ramanathan","year":"2009","journal-title":"Neonatology"},{"key":"2021120900404776300_B21","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1038\/jp.2008.50","article-title":"Surfactants: past, present and future","volume":"28","author":"Halliday","year":"2008","journal-title":"J Perinatol"},{"key":"2021120900404776300_B22","unstructured":"Halahakoon\u2008W. A Study of Cerebral Function Following Surfactant Treatment for Respiratory Distress Syndrome\u2008[MD thesis]. Belfast, Northern Ireland: Queen's University; 1999"},{"key":"2021120900404776300_B23","first-page":"117","article-title":"A cost minimization comparison of two surfactants\u2014beractant and poractant alfa\u2014based upon prospectively designed, comparative clinical trial data","volume":"9","author":"Marsh","year":"2004","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"2","key":"2021120900404776300_B24","first-page":"92","article-title":"An open-label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources","volume":"11","author":"Gerdes","year":"2006","journal-title":"J Pediatr Pharmacol Ther"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/128\/6\/e1588\/845010\/zpe012110e1588.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/128\/6\/e1588\/845010\/zpe012110e1588.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T03:38:35Z","timestamp":1639798715000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/128\/6\/e1588\/31124\/Efficacy-of-Porcine-Versus-Bovine-Surfactants-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,1]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,12,1]]},"published-print":{"date-parts":[[2011,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2011-1395","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,1]]}}}